BostonGene will use its computational platform to find associations between tumor genetics, the immune system, and the effectiveness of new treatments.
BostonGene will contribute its genomic testing and bioinformatics capabilities to search for biomarkers and actionable targets in data from MSK's preclinical and clinical research programs.